{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:56:42Z","timestamp":1771678602280,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.det.2024.08.002","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T19:33:28Z","timestamp":1725996808000},"page":"11-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Innovations in Acne"],"prefix":"10.1016","volume":"43","author":[{"given":"Bruna Galvao de Oliveira","family":"Wafae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2024.08.002_bib1","article-title":"Evaluation of stigma toward individuals with acne","author":"Shields","year":"2023","journal-title":"JAMA Dermatology"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib7","first-page":"15","article-title":"A\u00a0review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris","volume":"85","author":"Del","year":"2010","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/ije\/dyv333","article-title":"Depression and the risk of severe infections: prospective analyses on a nationwide representative sample","volume":"45","author":"Andersson","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.det.2024.08.002_bib12","first-page":"577","article-title":"Prevalence of facial acne in adults","volume":"41","author":"Goulden","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.002_bib13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ced.12270","article-title":"What\u2019s new in acne? An analysis of systematic reviews published in 2011-2012","volume":"39","author":"Bhate","year":"2014","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.002_bib15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaad.2018.09.055","article-title":"Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments","volume":"80","author":"Barbieri","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.002_bib16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","article-title":"Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials","volume":"156","author":"Hebert","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.002_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jaad.2020.04.087","article-title":"Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris","volume":"83","author":"Eichenfield","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.002_bib18","first-page":"563","article-title":"Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study","volume":"18","author":"Mazzetti","year":"2019","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2133.2011.10332.x","article-title":"Cortexolone 17\u03b1-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0\u00b705% cream","volume":"165","author":"Trifu","year":"2011","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.002_bib20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jaad.2019.02.044","article-title":"Randomized phase 3 evaluation of trifarotene 50 \u03bcg\/g cream treatment of moderate facial and truncal acne","volume":"80","author":"Tan","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/jdv.15794","article-title":"Long-term safety and efficacy of trifarotene 50 \u03bcg\/g cream, a first-in-class RAR-\u03b3 selective topical retinoid, in patients with moderate facial and truncal acne","volume":"34","author":"Blume-Peytavi","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.det.2024.08.002_bib22","first-page":"E53","article-title":"A\u00a0randomized, controlled trial of trifarotene plus doxycycline for severe acne vulgaris","volume":"15","author":"Rosso","year":"2022","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.08.002_bib23","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s13555-023-01042-7","article-title":"Trifarotene reduces risk for atrophic acne scars: results from A phase 4 controlled study","volume":"13","author":"Schleicher","year":"2023","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2166346","article-title":"Low irritation potential of tazarotene 0.045% lotion: head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies","volume":"34","author":"Draelos","year":"2023","journal-title":"J\u00a0Dermatol Treat"},{"issue":"4","key":"10.1016\/j.det.2024.08.002_bib25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1370\/afm.2995","article-title":"Comparative efficacy of pharmacological treatments for acne vulgaris: a network meta-analysis of 221 randomized controlled trials","volume":"21","author":"Huang","year":"2023","journal-title":"Ann Fam Med"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2018.08.020","article-title":"A\u00a0novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies","volume":"80","author":"Gold","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.002_bib27","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaad.2019.05.078","article-title":"Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study","volume":"82","author":"Raoof","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.08.002_bib28","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3855\/jidc.6862","article-title":"In\u00a0vitro antimicrobial susceptibility patterns of Propionibacterium acnes isolated from patients with acne vulgaris","volume":"10","author":"Biswal","year":"2016","journal-title":"J\u00a0Infect Dev Ctries"},{"issue":"3","key":"10.1016\/j.det.2024.08.002_bib29","doi-asserted-by":"crossref","DOI":"10.12788\/cutis.0067","article-title":"Active comparator trial designs used to promote development of innovative new medications","volume":"106","author":"Barbieri","year":"2020","journal-title":"Cutis"},{"issue":"10","key":"10.1016\/j.det.2024.08.002_bib30","first-page":"1084","article-title":"Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 Years and older","volume":"17","author":"Tyring","year":"2018","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.08.002_bib31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.36849\/JDD.6945","article-title":"Vehicle formulation impacts tolerability and patient preference: comparison of tretinoin branded lotion and generic cream","volume":"21","author":"Draelos","year":"2022","journal-title":"J\u00a0Drugs Dermatol JDD"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib32","first-page":"70","article-title":"Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials","volume":"19","author":"Tanghetti","year":"2020","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.002_bib33","first-page":"542","article-title":"A\u00a0phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris","volume":"18","author":"Tanghetti","year":"2019","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.08.002_bib34","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s00403-023-02725-z","article-title":"Silica-based microencapsulation used in topical dermatologic applications","volume":"315","author":"Green","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.det.2024.08.002_bib35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaad.2023.05.093","article-title":"Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: results from two phase 3 double-blind, randomized, vehicle-controlled studies","volume":"89","author":"Del Rosso","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.002_bib36","first-page":"103","article-title":"Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial","volume":"86","author":"Yentzer","year":"2010","journal-title":"Cutis"},{"issue":"5","key":"10.1016\/j.det.2024.08.002_bib37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaad.2022.08.069","article-title":"Clindamycin phosphate 1.2%\/adapalene 0.15%\/benzoyl peroxide 3.1% gel for moderate-to-severe acne: efficacy and safety results from two randomized phase 3 trials","volume":"89","author":"Stein Gold","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01297-18","article-title":"Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris","volume":"63","author":"Zhanel","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.det.2024.08.002_bib39","first-page":"987","article-title":"Once-daily oral sarecycline 1.5 mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials","volume":"17","author":"Moore","year":"2018","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.08.002_bib40","first-page":"E53","article-title":"Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a phase III, multicenter, open-label study and a phase I phototoxicity study","volume":"12","author":"Pariser","year":"2019","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"key":"10.1016\/j.det.2024.08.002_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1033980","article-title":"Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity","volume":"9","author":"Grada","year":"2022","journal-title":"Front Med"},{"issue":"10","key":"10.1016\/j.det.2024.08.002_bib42","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jamadermatol.2023.2363","article-title":"Temporal trends in the use of systemic medications for acne from 2017 to 2020","volume":"159","author":"Barbieri","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.002_bib43","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/1523-1747.ep12472325","article-title":"Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5 alpha-dihydrotestosterone in\u00a0vitro","volume":"100","author":"Akamatsu","year":"1993","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2024.08.002_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074349","article-title":"Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial","volume":"381","author":"Santer","year":"2023","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.det.2024.08.002_bib45","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/1346-8138.15559","article-title":"Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"Patiyasikunt","year":"2020","journal-title":"J\u00a0Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.002_bib46","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaad.2022.01.010","article-title":"The need for potassium monitoring in women on spironolactone for dermatologic conditions","volume":"87","author":"Plante","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.002_bib47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijwd.2019.04.024","article-title":"Hyperkalemia in women with acne exposed to oral spironolactone: a retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program","volume":"5","author":"Thiede","year":"2019","journal-title":"Int J Womens Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.002_bib48","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamadermatol.2015.34","article-title":"Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne","volume":"151","author":"Plovanich","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2024.08.002_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1472-6904-11-23","article-title":"The association between drospirenone and hyperkalemia: a comparative-safety study","volume":"11","author":"Bird","year":"2011","journal-title":"BMC Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.det.2024.08.002_bib50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.contraception.2008.06.012","article-title":"Risk of hyperkalemia in women taking ethinylestradiol\/drospirenone and other oral contraceptives","volume":"78","author":"Loughlin","year":"2008","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.det.2024.08.002_bib51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.002_bib52","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamadermatol.2020.5468","article-title":"Temporal trends and clinician variability in potassium monitoring of healthy young women treated for acne with spironolactone","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.002_bib53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamadermatol.2021.5866","article-title":"Association of spironolactone use with risk of cancer: a systematic review and meta-analysis","volume":"158","author":"Bommareddy","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.002_bib54","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2020.05.081","article-title":"Spironolactone use does not increase the risk of female breast cancer recurrence: a retrospective analysis","volume":"83","author":"Wei","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.002_bib55","first-page":"30","article-title":"Patient awareness of antimicrobial resistance and antibiotic use in acne vulgaris","volume":"12","author":"Del Rosso","year":"2019","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.002_bib56","first-page":"632","article-title":"Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: a retrospective cohort study 2010-2016","volume":"17","author":"Barbieri","year":"2018","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib57","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/s13063-020-04432-w","article-title":"FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial","volume":"21","author":"Poinas","year":"2020","journal-title":"Trials"},{"issue":"12","key":"10.1016\/j.det.2024.08.002_bib58","first-page":"1238","article-title":"Optimizing the trial design for a comparative effectiveness study of spironolactone versus oral antibiotics for women with acne: a Delphi consensus panel","volume":"19","author":"Barbieri","year":"2020","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.002_bib59","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jaad.2014.03.051","article-title":"Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris","volume":"71","author":"Koo","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/pde.14391","article-title":"Use of spironolactone to treat acne in adolescent females","volume":"38","author":"Roberts","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.002_bib61","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/jdv.16302","article-title":"Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017","volume":"34","author":"Roberts","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.08.002_bib63","article-title":"Drug solubility: importance and enhancement techniques","volume":"2012","author":"Savjani","year":"2012","journal-title":"ISRN Pharm"},{"issue":"4","key":"10.1016\/j.det.2024.08.002_bib64","article-title":"Comparative pharmacokinetic profiles of a novel low-dose micronized-isotretinoin 32 mg formulation and lidose-isotretinoin 40 mg in fed and fasted conditions: two open-label, randomized, crossover studies in healthy adult participants","volume":"100","author":"Madan","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.det.2024.08.002_bib65","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/sj.jid.5701160","article-title":"Identification of histamine receptors and reduction of squalene levels by an antihistamine in sebocytes","volume":"128","author":"Pelle","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2340\/00015555-0355","article-title":"Acne itch: do acne patients suffer from itching?","volume":"88","author":"Reich","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"65","key":"10.1016\/j.det.2024.08.002_bib67","first-page":"14","article-title":"Efficacy of isotretinoin and antihistamine versus isotretinoin alone in the treatment of moderate to severe acne: a randomised control trial","volume":"17","author":"Pandey","year":"2019","journal-title":"Kathmandu Univ Med J"},{"issue":"12","key":"10.1016\/j.det.2024.08.002_bib68","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/jdv.12403","article-title":"Effect of antihistamine as an adjuvant treatment of isotretinoin in acne: a randomized, controlled comparative study","volume":"28","author":"Lee","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.08.002_bib69","article-title":"The role of oral nutraceuticals as adjunctive therapy to reduce side effects from isotretinoin: a systematic review","author":"Shields","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib70","first-page":"60","article-title":"Effectiveness of oral omega 3 in reducing mucocutaneous side effects of oral isotretinoin in patients with acne vulgaris","volume":"33","author":"Zainab","year":"2021","journal-title":"J\u00a0Ayub Med Coll Abbottabad"},{"key":"10.1016\/j.det.2024.08.002_bib71","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6974045","article-title":"Is oral omega-3 effective in reducing mucocutaneous side effects of isotretinoin in patients with acne vulgaris?","volume":"2018","author":"Mirnezami","year":"2018","journal-title":"Dermatol Res Pract"},{"issue":"5","key":"10.1016\/j.det.2024.08.002_bib72","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1177\/1120672120945655","article-title":"Efficacy of omega-3 fatty acids and punctal plugs in the prevention of isotretinoin-associated ocular surface disease","volume":"31","author":"Elhamaky","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaad.2019.06.025","article-title":"The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time","volume":"82","author":"Barbieri","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.08.002_bib74","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamadermatol.2022.2044","article-title":"Isotretinoin laboratory monitoring in acne treatment: a Delphi consensus study","volume":"158","author":"Xia","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.002_bib75","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjd.21840","article-title":"Is routine laboratory testing in healthy young patients taking isotretinoin necessary: a critically appraised topic","volume":"187","author":"Affleck","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.002_bib76","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/ijd.15089","article-title":"Isotretinoin in the management of acne vulgaris: practical prescribing","volume":"60","author":"Fallah","year":"2021","journal-title":"Int J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.002_bib78","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1007\/s10103-022-03645-6","article-title":"A\u00a0novel 1726-nm laser system for safe and effective treatment of acne vulgaris","volume":"37","author":"Scopelliti","year":"2022","journal-title":"Lasers Med Sci"},{"issue":"2","key":"10.1016\/j.det.2024.08.002_bib79","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/jocd.15602","article-title":"Selective photothermolysis with a novel 1726 nm laser beam: a safe and effective solution for acne vulgaris","volume":"22","author":"Goldberg","year":"2023","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.002_bib80","first-page":"847","article-title":"Use of intradermal botulinum toxin to reduce sebum production and facial pore size","volume":"7","author":"Shah","year":"2008","journal-title":"J\u00a0Drugs Dermatol JDD"},{"issue":"1","key":"10.1016\/j.det.2024.08.002_bib81","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/DSS.0000000000002494","article-title":"A\u00a0randomized, double-blinded study evaluating the safety and efficacy of AbobotulinumtoxinA injections for oily skin of the forehead: a dose-response analysis","volume":"47","author":"Kesty","year":"2021","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.det.2024.08.002_bib82","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/asj\/sju150","article-title":"Sebum production alteration after botulinum toxin type A injections for the treatment of forehead rhytides: a prospective randomized double-blind dose-comparative clinical investigation","volume":"35","author":"Min","year":"2015","journal-title":"Aesthet Surg J"},{"issue":"10","key":"10.1016\/j.det.2024.08.002_bib83","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/ijd.15574","article-title":"The effectiveness of botulinum toxin type A (BTX-A) in the treatment of facial skin oily seborrhea, enlarged pores, and symptom complex of post-acne","volume":"60","author":"Shirshakova","year":"2021","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.002_bib84","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/ijd.16519","article-title":"Long-pulsed Nd: YAG laser (1064 nm) versus intralesional botulinum toxin type (A) in acne vulgaris therapy: a split face study","volume":"62","author":"Ibrahim","year":"2023","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.002_bib85","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2023.05.070","article-title":"DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: results of a phase 2b randomized, double-blind, placebo-controlled trial","volume":"89","author":"Eichenfield","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.002_bib86","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bjd.21663","article-title":"Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial","volume":"187","author":"Picardo","year":"2022","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.002_bib89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40268-020-00299-z","article-title":"Efficacy and safety of VB-1953 topical gel in non-responder acne patients with clindamycin-resistant cutibacterium acnes","volume":"20","author":"Batra","year":"2020","journal-title":"Drugs R"},{"key":"10.1016\/j.det.2024.08.002_bib90","author":"Galderma"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:18:27Z","timestamp":1762309107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0733863524000743"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.08.002","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovations in Acne","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}